Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

All patients treated with aflibercept in combination with FOLFIRI for mCRC after failure of an oxaliplatin-containing regimen (including patients pretreated with bevacizumab or anti-EGFR and patients treated with oxaliplatin in the adjuvant setting).
Exclusively or predominantly hepatic metastases (≤ 5 pulmonary nodules \< 2 cm).
Age \> 18 years.
Signed consent for collection of personal and medical data.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

Concomitant participation in a clinical trial.
Patient receiving concomitant anti-VEGF agents and/or receiving aflibercept as part of a clinical trial or in a compassionate use program.
Patient receiving aflibercept in combination with chemotherapy other than FOLFIRI.
Patient with contra-indication to surgery.
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Resection Observatory